Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis

Objective To examine the diagnostic value of serum B-type natriuretic peptide (BNP) in acute Kawasaki disease (KD). Design Systematic review and meta-analysis. Data sources A systematic literature search strategy was designed and carried out using MEDLINE, EMBASE and the Cochrane Library from inception to December 2013. We also performed manual screening of the bibliographies of primary studies and review articles, and contacted authors for additional data. Study eligibility criteria We included all BNP and NT-pro (N-terminal prohormone) BNP assay studies that compared paediatric patients with KD to patients with febrile illness unrelated to KD. We excluded case reports, case series, review articles, editorials, congress abstracts, clinical guidelines and all studies that compared healthy controls. Primary and secondary outcome measures The performance characteristics of BNP were summarised using forest plots, hierarchical summary receiver operating characteristic (ROC) curves and bivariate random effects models. Results We found six eligible studies including 279 cases of patients with KD and 203 febrile controls. Six studies examined NT-proBNP and one examined BNP. In general, NT-proBNP is a specific and moderately sensitive test for identifying KD. The pooled sensitivity was 0.89 (95% CI 0.78 to 0.95) and the pooled specificity was 0.72 (95% CI 0.58 to 0.82). The area under the summary ROC curve was 0.87 (95% CI 0.83 to 0.89). The positive likelihood ratio (LR+ 3.20, 95% CI 2.10 to 4.80) was sufficiently high to be qualified as a rule-in diagnostic tool in the context of high pre-test probability and compatible clinical symptoms. A high degree of heterogeneity was found using the Cochran Q statistic. Conclusions Current evidence suggests that NT-proBNP may be used as a diagnostic tool for KD. NT-proBNP has high diagnostic value for identifying KD in patients with protracted undifferentiated febrile illness. Prospective large cohort studies are needed to help determine best cut-off values and further clarify the role of NT-proBNP in the diagnosis process of KD.

[1]  S. Fuse,et al.  N-terminal pro-brain natriuretic Peptide as a useful diagnostic marker of acute Kawasaki disease in children. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[2]  N. Dahdah,et al.  Value of amino‐terminal pro B‐natriuretic peptide in diagnosing Kawasaki disease , 2012, Pediatrics international : official journal of the Japan Pediatric Society.

[3]  J. Suh,et al.  Adjuvant laboratory marker of Kawasaki disease; NT-pro-BNP or hs-CRP? , 2011, Annals of clinical and laboratory science.

[4]  S. Chun,et al.  Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction , 2011, Korean journal of pediatrics.

[5]  Lingling Suo,et al.  [Meta-analysis of the risk factors for coronary artery lesion secondary to Kawasaki disease in Chinese children]. , 2011, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[6]  Xing-chang Zheng,et al.  [Levels of serum brain natriuretic peptide and the correlation to heart function in children with Kawasaki disease]. , 2010, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[7]  N. Dahdah,et al.  Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease , 2009, Pediatric Cardiology.

[8]  H. Yanagawa,et al.  Prevalence of coronary artery abnormality in incomplete Kawasaki disease , 2007, Pediatrics international : official journal of the Japan Pediatric Society.

[9]  A. Akobeng Understanding diagnostic tests 2: likelihood ratios, pre‐ and post‐test probabilities and their use in clinical practice , 2007, Acta paediatrica.

[10]  K. Takahashi,et al.  Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Diastolic Dysfunction in Children with Kawasaki Disease , 2005, Pediatric Cardiology.

[11]  Walter R Wilson,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Circulation.

[12]  R. Uehara,et al.  Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease , 2004, Pediatrics international : official journal of the Japan Pediatric Society.

[13]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[14]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[15]  H. Kawaguchi,et al.  Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease , 2000, Pediatrics international : official journal of the Japan Pediatric Society.

[16]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[17]  G. Takemura,et al.  Venticular expression of atrial and brain natriuretic peptides in patients with myocarditis. , 1995, International journal of cardiology.

[18]  G. Guyatt,et al.  Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test: B. What Are the Results and Will They Help Me In Caring for My Patients? , 1994 .

[19]  G. Guyatt,et al.  Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. , 1994, JAMA.

[20]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[21]  T. Nakada,et al.  Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequelae and regional wall motion abnormalities of the left ventricle. , 1992, Japanese circulation journal.

[22]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[23]  J. Newburger,et al.  Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. , 1991, The Journal of pediatrics.

[24]  R F Galbraith,et al.  A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.

[25]  T. Kamiya,et al.  Cardiac biopsy in Kawasaki disease , 1981, Heart and Vessels.

[26]  Y. Hamashima,et al.  Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.

[27]  Y. Takwoingi,et al.  Systematic Reviews of Diagnostic Test Accuracy , 2021, Principles and Practice of Systematic Reviews and Meta-Analysis.

[28]  岸本 慎太郎 Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease , 2012 .

[29]  M. Rauh,et al.  NT-Pro-B-type Natriuretic Peptide in Infants and Children: Reference Values Based on Combined Data from Four Studies , 2008, Pediatric Cardiology.

[30]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[31]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system , 1996 .

[32]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[33]  J. Newburger,et al.  Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. , 1991, The Journal of pediatrics.